Shandong Cancer Hospital And Institute

This phase II trial tests whether adding a precise, high-dose form of radiation (SBRT) to standard maintenance chemotherapy can help people with advanced pancreatic cancer live longer. The study enrolls 24 adults whose cancer has not grown after at least four months of initial ch…

This Phase II trial tests whether adding a dual immunotherapy drug (iparomlimab/tuvonralimab) to standard chemoradiotherapy can improve outcomes for patients with locally advanced rectal cancer that has a specific genetic profile (pMMR/MSS), which usually does not respond to immu…

This study tests a new treatment plan for people with advanced liver cancer that has spread to blood vessels or a few other spots. The plan combines chemotherapy directly into the liver, two immunotherapy drugs, a targeted therapy, and precise radiation. The goal is to see if thi…

This phase 2 trial is testing whether adding the immunotherapy drug sintilimab to chemotherapy and radiation can help people with inoperable pancreatic cancer live longer. The study will enroll 25 participants who have not had prior treatment. Researchers will track how long the …

This study looks at colorectal cancer patients whose disease is under control (no evidence of disease) but later develop a small number of lung tumors. Instead of starting chemotherapy right away, doctors will treat the lung spots with surgery or radiation and then watch closely.…

This study tests whether adding radiotherapy to a drug combination (fruquintinib and sintilimab) can help control colorectal cancer that has spread to the liver and hasn't responded to two prior treatments. About 62 adults with a specific type of colorectal cancer (MSS/pMMR) will…

This study tests a new drug called ivonescimab, combined with targeted radiation and chemotherapy, for people with locally advanced pancreatic cancer that cannot be removed by surgery. The trial has two phases: first, finding the safest dose of ivonescimab, then checking how well…

This study compares two treatments for advanced liver cancer (BCLC stage C): standard drug therapy alone versus drug therapy plus a precise type of radiation called stereotactic body radiotherapy (SBRT). The goal is to see if adding radiation helps people live longer. About 184 a…

This study compares a new type of radiation therapy (SFRT) to standard radiation for people with large soft tissue sarcomas (tumors at least 5 cm). About 106 participants will be randomly assigned to one of the two treatments. The goal is to see if SFRT can shrink tumors better a…

This phase 3 trial compares two different oral chemotherapy drugs given alongside radiation before surgery for locally advanced rectal cancer. The standard drug, capecitabine, is being tested against a newer drug called TAS-102. The goal is to see if TAS-102 leads to more tumors …

This study is for people with endometrial cancer that has come back or spread to a few other spots. It tests a new drug called cadonilimab given together with standard chemotherapy and radiation. The goal is to see if this combination can shrink tumors and help people live longer…

This study tests whether adding an antifungal drug (posaconazole) to standard immunotherapy and chemotherapy can help more women with triple-negative breast cancer achieve a complete response before surgery. About 72 women with early-stage, high-risk disease will be randomly assi…

This study tests whether adding the targeted drug nimotuzumab to standard radiation therapy helps control advanced head and neck cancer better than radiation alone. It is for 335 adults whose cancer has spread locally but who cannot take platinum-based chemotherapy. The main goal…

This study tests a new nano-formulation of megestrol acetate, a drug used to stimulate appetite and promote weight gain, in patients with advanced pancreatic cancer who suffer from anorexia-cachexia syndrome. The trial will enroll 56 patients and compare those receiving the nano-…

This study looks at whether a very high level of a protein called HER2 (measured by the HER2/CEP17 ratio) affects how well breast cancer patients do after treatment with a combination of two targeted drugs (trastuzumab and pertuzumab). Researchers will review medical records of 3…